MHRA Introduces New Device Registration Fee: What Manufacturers Need to Know
The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has updated its “DORS Fees Guidance 2.1”, introducing a new annual fee model for device registration.
MedNet EC-REP
Author

From One-Time to Annual Fee
- Until 31 March 2026, MHRA continues to apply the existing £261 one-off registration fee.
- From 1 April 2026, a recurring annual fee will replace the one-off fee, based on the number of chargeable GMDN® Level 2 categories (or Level 1 if Level 2 is not defined).
- Fees will apply per category rather than per device, with pro-rata charges for new devices added mid-year.
Fee Calculation and Payment
- Annual fees are estimated at around £300 per GMDN category.
- MHRA will base fees on a snapshot of registered categories on 31 March each year.
- Payment is due within 90 days of invoicing, and non-payment may suspend registration access.
Changes and Exemptions
- Updating Letters of Designation, organisation name, or address will no longer incur fees.
- Re-registering devices in previously paid categories will not trigger additional charges.
- Only registration of new devices in chargeable categories triggers fees.
Preparing for the New System
Manufacturers and UK Responsible Persons should:
- Review device portfolios and ensure correct GMDN® category assignments before 30 March 2026.
- Verify contact and company information in the MHRA DORS system.
- Plan for the annual payment cycle, starting from 1 April 2026, and budget accordingly.
The shift to an annual fee model supports enhanced post-market surveillance, sustainable regulatory oversight, and encourages accurate device registrations.
Source: MHRA
Related Articles

IVDR Rule 7: When Is IVD Control Material Class B? (MDCG 2020-16 Rev. 5)
MDCG 2020-16 Rev. 5 clarifies when IVD control material without an assigned value falls under class B, and when another rule applies.

MHRA Consultation 2026: The Fee Increases Coming for Medical Device Manufacturers in 2027
The MHRA has opened a consultation on fee increases from April 2027 — including a proposed 70 % rise in the post-market surveillance fee. Manufacturers have until 25 September to respond.

New EU Study: Where Manufacturers and Authorised Representatives Really Stand on MDR and IVDR
New EU study finds 48% of manufacturers have withdrawn devices from the market. Key MDR/IVDR and AR findings for 2026. Read the numbers now.
Stay Updated
Get the latest regulatory updates and industry insights delivered to your inbox.
Subscribe to Updates